Based on reported financial statement history.
Over longer horizons, Revenue CAGR averages -3.05% over 3 years and -1.18% over 5 years; the trailing 12 months came in at +26.19%.The TTM figure compares the trailing 12 months (sum of the latest four quarters) with the 12 months before that. Rows in the history table compare fiscal years, and the quarterly table compares single quarters; the three measure different windows and will differ. Revenue CAGR measures how the company's top-line revenue has grown over time. Consistent revenue growth is a key indicator of business expansion and market share gains.
Ironwood Pharmaceuticals, Inc. (IRWD)
Revenue growth vs the same fiscal quarter in the prior fiscal year, last 40 comparable quarters.
Reported quarterly revenue; no daily interpolation. Q2 FY2026 (2026-06-30): $113.04M.
FMP quote market capitalization / revenue from four consecutive issuer fiscal quarters Quote observation: 2026-10-06T14:52:41.025Z. Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation. Historical series through 2026-10-05.
| Year | Start Revenue | End Revenue | Change | % Change |
|---|---|---|---|---|
| 2025 | $351.41M | $296.15M | −$55.26M | -15.72% |
| 2024 | $442.74M | $351.41M | −$91.33M | -20.63% |
| 2023 | $410.60M | $442.74M | +$32.14M | +7.83% |
| 2022 | $413.75M | $410.60M | −$3.16M | -0.76% |
| 2021 | $389.52M | $413.75M | +$24.23M | +6.22% |
| 2020 | $428.41M | $389.52M | −$38.89M | -9.08% |
| 2019 | $346.64M | $428.41M | +$81.77M | +23.59% |
| 2018 | $298.28M | $346.64M | +$48.36M | +16.21% |
| 2017 | $273.96M | $298.28M | +$24.32M | +8.88% |
| 2016 | $149.56M | $273.96M | +$124.40M | +83.18% |
| 2015 | $76.44M | $149.56M | +$73.12M | +95.66% |
| 2014 | $22.88M | $76.44M | +$53.55M | +234.06% |
| 2013 | $150.25M | $22.88M | −$127.36M | -84.77% |
| 2012 | $65.87M | $150.25M | +$84.37M | +128.09% |
| 2011 | $43.86M | $65.87M | +$22.01M | +50.19% |
| 2010 | $36.10M | $43.86M | +$7.75M | +21.48% |
| 2009 | $22.22M | $36.10M | +$13.89M | +62.50% |
| 2008 | $10.46M | $22.22M | +$11.75M | +112.31% |
| 2007 | $3.14M | $10.46M | +$7.32M | +233.25% |
| Period | Period End | Value | QoQ Growth | YoY Growth |
|---|---|---|---|---|
| Q2 FY2026 | 2026-06-30 | $113.04M | +6.1% | +32.6% |
| Q1 FY2026 | 2026-03-31 | $106.51M | +123.2% | +158.9% |
| Q4 FY2025 | 2025-12-31 | $47.71M | -60.9% | -47.3% |
| Q3 FY2025 | 2025-09-30 | $122.06M | +43.2% | +33.3% |
| Q2 FY2025 | 2025-06-30 | $85.24M | +107.2% | -9.7% |
| Q1 FY2025 | 2025-03-31 | $41.14M | -54.6% | -45.1% |
Current FMP quote-based enterprise value / four-quarter revenue Quote observation: 2026-10-06T14:52:41.025Z. Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation. Historical series through 2026-10-05.
| Q4 FY2024 | 2024-12-31 | $90.55M | -1.1% | -23.0% |
| Q3 FY2024 | 2024-09-30 | $91.59M | -3.0% | -19.5% |
| Q2 FY2024 | 2024-06-30 | $94.40M | +26.1% | -12.1% |
| Q1 FY2024 | 2024-03-31 | $74.88M | -36.3% | -28.0% |
| Q4 FY2023 | 2023-12-31 | $117.55M | +3.4% | +9.7% |
| Q3 FY2023 | 2023-09-30 | $113.74M | +5.9% | +4.7% |
| Q2 FY2023 | 2023-06-30 | $107.38M | +3.2% | +10.4% |
| Q1 FY2023 | 2023-03-31 | $104.06M | -2.9% | +6.7% |
| Q4 FY2022 | 2022-12-31 | $107.20M | -1.3% | -8.5% |
| Q3 FY2022 | 2022-09-30 | $108.64M | +11.7% | +4.7% |
QoQ Growth compares the previous fiscal quarter; YoY Growth compares the same fiscal quarter in the prior fiscal year. Missing or ambiguous fiscal periods render N/A.
